Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: CMM003
MIFTS: 41

Common Wart

Categories: Infectious diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Common Wart

About this section

MalaCards integrated aliases for Common Wart:

Name: Common Wart 12 15 73

Classifications:

MalaCards categories:
Global: Infectious diseases
See all MalaCards categories (disease lists)
ICD10: 33


Sources

Summaries for Common Wart

About this section
Disease Ontology : 12 A viral infectious disease that results in infection located in skin, has material basis in human papillomavirus (types 2 and 4). This infection has symptom raised wart with roughened surface, most common on hands, but can grow anywhere on the body.

MalaCards based summary : Common Wart is related to haemophilus influenzae and mycobacterium abscessus, and has symptoms including raised wart An important gene associated with Common Wart is CLEC7A (C-Type Lectin Domain Containing 7A), and among its related pathways/superpathways are Innate Immune System and Tuberculosis. The drugs Miconazole and Salicylic acid have been mentioned in the context of this disorder. Affiliated tissues include skin, skin and testes, and related phenotypes are hematopoietic system and immune system

Sources

Related Diseases for Common Wart

About this section

Diseases related to Common Wart via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 21)
# Related Disease Score Top Affiliating Genes
1 haemophilus influenzae 10.3 CLEC7A CXCL8
2 mycobacterium abscessus 10.3 CLEC7A CXCL8
3 gnathomiasis 10.3 CD40 TET2
4 invasive aspergillosis 10.3 CLEC7A CXCL8
5 opportunistic mycosis 10.1 CLEC6A CLEC7A
6 dengue hemorrhagic fever 10.1 CD209 CXCL8
7 exanthema subitum 10.1 CD40 CD80
8 severe acute respiratory syndrome 10.0 CD209 CXCL8
9 bare lymphocyte syndrome, type i 10.0 CD40 CD80
10 lymphadenitis 9.9 CD209 CXCL8
11 aspergillosis 9.8 CD209 CLEC7A
12 mumps 9.8
13 measles 9.8
14 rubella 9.8
15 epidermodysplasia verruciformis 9.7
16 lymphedema 9.7
17 squamous cell carcinoma 9.7
18 melanoma 9.7
19 conjunctivitis 9.7
20 molluscum contagiosum 9.7
21 bowen's disease 9.7

Graphical network of the top 20 diseases related to Common Wart:



Diseases related to Common Wart
Sources

Symptoms & Phenotypes for Common Wart

About this section

Symptoms:

12
  • • raised wart

MGI Mouse Phenotypes related to Common Wart:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.5 CD40 CD80 CLEC4E CLEC6A CLEC7A LGALS3
2 immune system MP:0005387 9.17 CLEC7A LGALS3 TET2 CD40 CD80 CLEC4E
Sources

Drugs & Therapeutics for Common Wart

About this section

Drugs for Common Wart (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 145)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3 22916-47-8 4189
2
Salicylic acid Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3 69-72-7 338
3
Imiquimod Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 99011-02-6 57469
4
Zinc Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 7440-66-6 23994
5
Fluorouracil Approved Phase 4 51-21-8 3385
6 Analgesics Phase 4,Phase 2,Phase 3
7 Analgesics, Non-Narcotic Phase 4,Phase 2,Phase 3
8 Antifungal Agents Phase 4,Phase 2,Phase 3
9 Anti-Infective Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
10 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3
11 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 2,Phase 3
12 Antirheumatic Agents Phase 4,Phase 2,Phase 3
13 Cyclooxygenase Inhibitors Phase 4,Phase 2,Phase 3
14 Dermatologic Agents Phase 4,Phase 2,Phase 3,Not Applicable
15 Keratolytic Agents Phase 4,Phase 2,Phase 3,Not Applicable
16 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Not Applicable
17 Salicylates Phase 4,Phase 2,Phase 3
18 Liver Extracts Phase 4,Phase 3
19 Vaccines Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
20 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
21 Adjuvants, Immunologic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
22 Interferon Inducers Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
23 interferons Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
24 Antibodies Phase 4,Phase 3,Phase 1
25 Antibodies, Monoclonal Phase 4,Phase 3,Phase 1
26 Calcineurin Inhibitors Phase 4
27 Cyclosporins Phase 4
28 Immunoglobulins Phase 4,Phase 3,Phase 1
29 Micronutrients Phase 4,Phase 2,Phase 3,Not Applicable
30 Trace Elements Phase 4,Phase 2,Phase 3,Not Applicable
31 Antimetabolites Phase 4,Phase 1,Phase 2
32 Antimetabolites, Antineoplastic Phase 4,Phase 1,Phase 2
33 pyruvate Nutraceutical Phase 4,Phase 2,Phase 3
34
Catechin Nutraceutical Phase 4,Phase 1 154-23-4 9064
35
Epicatechin Investigational, Nutraceutical Phase 4,Phase 1 490-46-0 72276
36 Tea Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1
37
Ethanol Approved Phase 2, Phase 3,Not Applicable 64-17-5 702
38
Petrolatum Approved, Investigational Phase 2, Phase 3 8009-03-8
39
Aminolevulinic acid Approved Phase 3 106-60-5 137
40
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
41
Pancrelipase Approved, Investigational Phase 3 53608-75-6
42
Benzocaine Approved, Investigational Phase 3,Not Applicable 1994-09-7, 94-09-7 2337
43
Furosemide Approved, Vet_approved Phase 3,Phase 2 54-31-9 3440
44
Lenograstim Approved, Investigational Phase 3 135968-09-1
45
Zinc sulfate Approved, Investigational Phase 3,Not Applicable 7733-02-0
46 tannic acid Approved, Nutraceutical Phase 3,Not Applicable
47
Methionine Approved, Nutraceutical Phase 3 63-68-3 6137
48 Pharmaceutical Solutions Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable
49 Alkylating Agents Phase 3
50 Antineoplastic Agents, Alkylating Phase 3

Interventional clinical trials:

(show top 50) (show all 197)
# Name Status NCT ID Phase Drugs
1 17% Salicylate Versus 17% Salicylate-Ethyl Pyruvate for Plantar Foot Warts Unknown status NCT01712295 Phase 4 17% Salicylate with ethyl pyruvate;Salicylates
2 Does the HPV Vaccine Cause the Same Response in Adolescent Kidney and Liver Transplant Patients as in Healthy Controls? Unknown status NCT01101750 Phase 4
3 Imiquimod 5% Cream in the Treatment of External Genital or Perianal Warts in HIV+ Patients Completed NCT00761371 Phase 4 Imiquimod 5% cream
4 Study of Imiquimod Cream Prior to Ablative Therapy in External Ano-Genital Warts Completed NCT00189293 Phase 4 Imiquimod
5 Investigating Veregen â„¢ 15% Ointment Treatment For Non-facial Verrucae in Pediatric Patients: A Pilot Study Completed NCT02622568 Phase 4 Veregen only
6 Pharmacokinetic Study of Topically Applied Veregen 15% Compared With Oral Intake of Green Tea Beverage Completed NCT01082302 Phase 4 Polyphenon E (Veregen) 15% ointment
7 Alternate Dosing Schedules Study for HPV Vaccine Completed NCT00862810 Phase 4
8 Open-label Study of Subcutaneous Secukinumab to Evaluate Efficacy and Safety in Patients With Plaque Psoriasis Who Had Inadequate Response to Cyclosporine A Completed NCT02547714 Phase 4 Secukinumab (AIN457)
9 Intralesional Measles, Mumps, Rubella (MMR) Vaccine Versus Cryotherapy in Treatment of Multiple Common and Planter Warts Recruiting NCT03183765 Phase 4 Measles-Mumps-Rubella Vaccine
10 Scientific Evaluation of One or Two Doses of the Bivalent or Nonavalent Prophylactic HPV Vaccines Recruiting NCT03180034 Phase 4
11 Immunogenicity and Safety of Human Papilloma Virus Vaccine in Solid Organ Transplant Recipients Active, not recruiting NCT02624349 Phase 4 Quadravalent human papillomavirus vaccine
12 HPV (Human Papilloma Virus) Vaccination After Treatment of Anal Intraepithelial Neoplasia (AIN) Active, not recruiting NCT02087384 Phase 4 Placebo
13 The Efficacy of Intra-lesional Bleomycin Versus Intra-lesional Purified Protein Derivative in Treatment of Palmoplantar Warts Not yet recruiting NCT03477448 Phase 4 Bleomycin;Purified Protein Derivative
14 A RTC to Examine the Effectiveness of 400 mg of Oral Zinc Gluconate as Adjunctive Therapy for Ano-genital Warts Terminated NCT01468636 Phase 4 Oral Zinc;Placebo
15 Comparison of Five Treatments in Patients With Plantar Warts Terminated NCT01059110 Phase 4 Salicylate ointment;Imiquimod;5-Fluoro-Uracil;Cryotherapy
16 Pyruvic Acid Versus Salicylic Acid Preparation in Treatment of Plantar Warts Unknown status NCT02151630 Phase 2, Phase 3 Pyruvic acid;Salicylic Acid
17 Efficacy of Laser Versus Cryotherapy in the Treatment of Warts Unknown status NCT01808443 Phase 3
18 Two-dose Schedule of Quadrivalent HPV Recombinant Vaccine in 11-year-old Boys in Mexico City Unknown status NCT02382900 Phase 3
19 Phase 3 Study of Imiquimod Creams in the Treatment of External Genital Warts Completed NCT00735462 Phase 3 2.5% imiquimod cream;3.75% imiquimod cream;Placebo cream
20 Safety and Effectiveness Study of Imiquimod Creams in the Treatment of External Genital Warts Completed NCT00674739 Phase 3 Imiquimod;3.75% imiquimod cream;placebo cream
21 Oral Zinc Gluconate as Treatment for Recalcitrant Cutaneous Warts: A Randomized, Double-blind, Placebo-controlled Trial Completed NCT01783353 Phase 2, Phase 3
22 Low Dose Cyclophosphamide Treats Genital Warts Completed NCT00999986 Phase 3 cyclophosphamide
23 Glizigen-Viudid-External Anogenital Warts in Children and Adolescents Completed NCT01111344 Phase 3
24 Cervical Intraepithelial Neoplasm (CIN)-Warts Efficacy Trial in Women (Gardasil)(V501-013)(COMPLETED) Completed NCT00092521 Phase 3
25 Efficacy and Safety Study of Polyphenon E to Treat External Genital Warts Completed NCT00449982 Phase 3 Polyphenon E Ointment 10%, Polyphenon E Ointment 15%
26 An Investigational Study of Gardasilâ„¢ (qHPV Vaccine) in Reducing the Incidence of Anogenital Warts in Young Men (V501-020) Completed NCT00090285 Phase 3
27 PDT With Metvix® 160 mg/g Cream in Organ Transplant Recipients With Non-melanoma Skin Cancer Completed NCT00472459 Phase 3
28 Study to Test the Safety of HPV Vaccine in Women (V501-011)(COMPLETED) Completed NCT00517309 Phase 3
29 A Controlled Trial to Assess the Immunogenicity of a Proposed Paediatric Dosing Schedule of Human Papillomavirus Vaccine Completed NCT00501137 Phase 3
30 Cervical Intraepithelial Neoplasm (CIN) in Women (Gardasil)(V501-015) Completed NCT00092534 Phase 3
31 Study of an Investigational Vaccine in Pre-Adolescents and Adolescents (Gardasil)(V501-016) Completed NCT00092495 Phase 3
32 Immunogenicity Bridge Between an Investigational Monovalent Vaccine and the Equivalent Component of Gardasil (V501) a Quadrivalent Vaccine (V501-012)(COMPLETED) Completed NCT00092482 Phase 3
33 A Study of V503, a 9-valent Human Papillomavirus (9vHPV) Vaccine in Females 12-26 Years of Age Who Have Previously Received GARDASILâ„¢ (V503-006) Completed NCT01047345 Phase 3
34 Safety and Immunogenicity of Human Papillomavirus (HPV) Vaccine in Solid Organ Transplant Recipients Completed NCT00677677 Phase 3
35 Multivalent HPV (Human Papillomavirus) Vaccine Study in 16- to 26-Year Old Men and Women (V503-003) Completed NCT01651949 Phase 3
36 Protecting Young Special Risk Females From Cervical Cancer Through Human Papilloma Virus (HPV) Vaccination Completed NCT00964210 Phase 3 Licensed quadrivalent HPV vaccine, Gardasil
37 Immunogenicity of GlaxoSmithKline Biological's Human Papillomavirus (HPV) Vaccine (580299) Versus Merck's Gardasil® in Healthy Females 18-45 Years of Age Completed NCT00423046 Phase 3
38 Topical Green Tea Ointment in Treatment of Superficial Skin Cancer Completed NCT02029352 Phase 2, Phase 3 Sinecatechins 10%;Placebo
39 Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001) Completed NCT00543543 Phase 3
40 A Study to Evaluate the Safety, Immune Response, and Efficacy of Gardasil (V501, qHPV) in Mid-Adult Women (V501-019) Completed NCT00090220 Phase 3
41 A Study of Gardasil (V501) in Preadolescents and Adolescents (V501-018) Completed NCT00092547 Phase 3
42 GARDASILâ„¢ Study in Healthy Females Between 9 and 26 Years of Age in Sub-Saharan Africa (V501-046) Completed NCT01245764 Phase 3
43 Efficacy and Safety of Intravenous and Subcutaneous Secukinumab in Moderate to Severe Chronic Plaque-type Psoriasis Completed NCT01412944 Phase 3 secukinumab 150mg;secukinumab 10mg/kg i.v. regimen
44 Study to Assess the Efficacy, Safety and Tolerability of Secukinumab in Japanese Subjects With Generalized Pustular Psoriasis (GPP) Completed NCT01952015 Phase 3
45 Comparison Between Podofilox Topical Gel 0.5% and Allergan's Condylox® Gel 0.5% for External Anogenital Warts Recruiting NCT03532776 Phase 3 Podofilox Gel 0.5%;Condylox Topical Gel 0.5%;Placebo Gel
46 Efficacy of Quadrivalent HPV Vaccine to Prevent Relapses of Genital Warts After Initial Therapeutic Response Recruiting NCT03296397 Phase 3
47 Plerixafor Versus G-CSF in the Treatment of People With WHIM Syndrome Recruiting NCT02231879 Phase 3 Plerixafor;G-CSF
48 A Trial of X4P-001 in Patients With WHIM Syndrome Recruiting NCT03005327 Phase 2, Phase 3 X4P-001;Placebo
49 Study of Safety, Tolerability and Immunogenicity of Gardasil®9 in Immunocompromised Patients Recruiting NCT03525210 Phase 3
50 Radiotherapy or Imiquimod in Complex Lentigo Maligna Recruiting NCT02394132 Phase 3 Imiquimod

Search NIH Clinical Center for Common Wart

Sources

Genetic Tests for Common Wart

About this section
Sources

Anatomical Context for Common Wart

About this section

The Foundational Model of Anatomy Ontology organs/tissues related to Common Wart:

19
Skin

MalaCards organs/tissues related to Common Wart:

41
Skin, Testes, Liver, Kidney, T Cells, Bone
Sources

Publications for Common Wart

About this section

Articles related to Common Wart:

(show all 30)
# Title Authors Year
1
Hyperkeratotic acral melanoma mimicking a common wart. ( 25973355 )
2015
2
Measles, mumps, and rubella vaccine: a new option to treat common warts? ( 23786798 )
2013
3
Keratotic horn on left fifth fingertip: congenital ectopic nail misdiagnosed as a common wart. ( 22277059 )
2013
4
Comparative study of topical 80% trichloroacetic acid with 35% trichloroacetic acid in the treatment of the common wart. ( 23135096 )
2012
5
Intralesional immunotherapy of common warts: successful treatment with mumps, measles and rubella vaccine. ( 20202055 )
2010
6
Treatment options for the common wart. ( 18210913 )
2007
7
Plantar verrucous carcinoma (epithelloma cuniculatum): rare form of the common wart. ( 17214114 )
2006
8
A genotype distribution of human papillomaviruses detected by polymerase chain reaction and direct sequencing analysis in a large sample of common warts in Japan. ( 16032719 )
2005
9
Molecular analysis of the effect of topical imiquimod treatment of HPV 2/27/57-induced common warts. ( 15452412 )
2004
10
Human leukocyte antigen class II alleles and natural history of HPV 2/27/57-induced common warts. ( 15257408 )
2004
11
Is duct tape occlusion therapy as effective as cryotherapy for the treatment of the common wart? ( 12361441 )
2002
12
The efficacy of duct tape vs cryotherapy in the treatment of verruca vulgaris (the common wart). ( 12361440 )
2002
13
Human papillomavirus associated Bowen's disease of the foot: unique clinical features mimicking a common wart. ( 11525958 )
2001
14
Self-administered topical 5% imiquimod for the treatment of common warts and molluscum contagiosum. ( 11069514 )
2000
15
Simultaneously detected aberrant p53 tumor suppressor protein and HPV-DNA localize mostly in separate keratinocytes in anogenital and common warts. ( 8734914 )
1996
16
Efficacious treatment of the common wart (verruca vulgaris). ( 1462533 )
1992
17
[Systemic treatment of common warts with beta-interferon]. ( 1917463 )
1991
18
Common wart causing longitudinal groove in nail. ( 28150682 )
1986
19
Characterization of two HPV-3 related papillomaviruses from common warts that are distinct clinically from flat warts or epidermodysplasia verruciformis. ( 6302170 )
1983
20
Transformation of the common wart into squamous cell carcinoma in a patient with primary lymphedema. ( 7248909 )
1981
21
Stump the experts. A common wart. ( 7338585 )
1981
22
An unusual transformation of a common wart in a child. ( 6269499 )
1981
23
The common wart: intralesional treatment with bleomycin sulfate. ( 6159138 )
1980
24
Treatment of the common wart by induced allergic inflammation. ( 7389963 )
1980
25
Treatment of the common wart with a virus vaccine. ( 14477428 )
1962
26
Morphological characterization of the virus of the human common wart (verruca vulgaris). ( 13785470 )
1961
27
Aralen and plaquenil in treatment of the common wart. ( 13726985 )
1961
28
Common wart conjunctivitis. ( 13196997 )
1954
29
Treatment of the common wart by x-ray therapy. ( 13164671 )
1954
30
Contact x-ray therapy of the common wart. ( 14914174 )
1952
Sources

Variations for Common Wart

About this section
Sources

Expression for Common Wart

About this section
Search GEO for disease gene expression data for Common Wart.
Sources

Pathways for Common Wart

About this section

Pathways related to Common Wart according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Innate Immune System 66
Show member pathways
 13.35 CD209 CD40 CD80 CLEC4E CLEC6A CLEC7A
2
Tuberculosis 37
11.69 CD209 CLEC4E CLEC7A
3
CLEC7A (Dectin-1) signaling 66
Show member pathways
 11.67 CD209 CLEC4E CLEC6A CLEC7A
4
T Cell Co-Signaling Pathway: Ligand-Receptor Interactions 65
11.22 CD40 CD80
5
B Cell Development Pathways 65
11.16 CD40 CD80
6
C-type lectin receptor signaling pathway 37
Show member pathways
 11.16 CD209 CLEC4E CLEC6A CLEC7A
7
Interleukin-10 signaling 66
11.09 CD80 CXCL8
8
Malaria 37
11.06 CD40 CXCL8
9
Inflammatory Response Pathway 1
10.84 CD40 CD80
Sources

GO Terms for Common Wart

About this section

Cellular components related to Common Wart according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 8.8 CD209 CD40 CD80

Biological processes related to Common Wart according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.71 CD40 CD80 CLEC4E CXCL8
2 innate immune response GO:0045087 9.55 CD209 CLEC4E CLEC6A CLEC7A LGALS3
3 cellular response to lipopolysaccharide GO:0071222 9.5 CD40 CD80 CXCL8
4 neutrophil chemotaxis GO:0030593 9.48 CXCL8 LGALS3
5 positive regulation of T cell proliferation GO:0042102 9.46 CD209 CD80
6 positive regulation of cytokine secretion GO:0050715 9.43 CLEC4E CLEC6A
7 defense response to protozoan GO:0042832 9.37 CD40 CLEC7A
8 regulation of T cell proliferation GO:0042129 9.26 CD209 LGALS3
9 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.26 CD209 CLEC4E CLEC6A CLEC7A
10 immune system process GO:0002376 9.1 CD209 CD40 CLEC4E CLEC6A CLEC7A LGALS3

Molecular functions related to Common Wart according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 carbohydrate binding GO:0030246 9.02 CD209 CLEC4E CLEC6A CLEC7A LGALS3
Sources

Sources for Common Wart

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....